$2.525
-0.063 (-2.51%)At close
OKUR News
OKUR Events
OnKure Plans IND Submissions for 2027
"We continue to advance the development of next-generation PI3Kalpha pan-mutant-selective inhibitors through our pipeline, including OKI-355 in vascular anomalies and OKI-345 in breast cancer. Both of our lead programs remain on track for IND submissions in the first half of 2027," said Nicholas Saccomano, President and Chief Executive Officer of OnKure.
OnKure Advances PI3Kalpha Inhibitor Development, Plans IND Submission in 2027
"Following our strategic transformation earlier this year, we continue to advance our next-generation PI3Kalpha pan-mutant selective inhibitor pipeline, which we believe represents the most compelling opportunity to deliver differentiated therapies across PI3Kalpha-driven diseases," said Nicholas Saccomano, President and Chief Executive Officer of OnKure. "Both OKI-355 and OKI-345 continue to advance through IND-enabling activities and remain on track for planned IND submissions in the first half of 2027. We believe the combination of our chemistry platform and deep understanding of PI3Kalpha biology positions us to develop differentiated therapies with the potential to meaningfully improve outcomes for patients. Our recent Key Opinion Leader event reinforced the scientific rationale underpinning our strategy and highlighted the significant opportunity for next-generation PI3Kalpha pan-mutant selective inhibitors to overcome the limitations of current therapies across multiple disease settings."
OnKure Focuses on PI3Kalpha New Drug Development
"During the first quarter, we sharpened our strategic focus on advancing our next generation PI3Kalpha pan-mutant selective inhibitor programs, which we believe represent the most compelling opportunity to deliver differentiated therapies across PI3Kalpha-driven diseases," said Nicholas Saccomano, President and Chief Executive Officer of OnKure. "Building on insights gained from our earlier clinical and translational work, we have advanced two highly selective pan-mutant development candidates that were purpose designed to achieve robust target coverage while avoiding class limiting toxicities. As we move forward with OKI-355 in vascular anomalies and OKI-345 in breast cancer, our focus is on translating the strengths of our chemistry platform and deep understanding of PI3Kalpha biology into programs with the potential to deliver meaningful, differentiated, and durable benefit to patients."
OnKure Therapeutics Files to Sell 36.14M Shares of Class A Common
OnKure Therapeutics files to sell 36.14M shares of Class A common for holders
OnKure Therapeutics Completes $150M Private Placement
OnKure Therapeutics announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of approximately $150M. OnKure intends to use the net proceeds from the private placement to fund the preclinical and clinical development of its next-generation PI3Ka pan-mutant-selective inhibitor candidates in breast cancer and vascular anomalies, as well as for working capital and general corporate purposes. Pursuant to the terms of the securities purchase agreement, OnKure has agreed to sell an aggregate of 26,713,636 shares of its Class A common stock at a purchase price of $4.15 per share and, in lieu of common stock, pre-funded warrants to purchase 9,430,959 shares of common stock at a purchase price of $4.1499 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and will be immediately exercisable. The private placement is expected to close on March 31, subject to satisfactory closing conditions. With the net proceeds from the private placement, OnKure expects to extend its cash runway into 2029. Leerink Partners is acting as lead placement agent for the financing. Evercore ISI, LifeSci Capital, and Oppenheimer & Co. are serving as co-placement agents for the financing.
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.